Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Regulatory News
SFDA warns against ADRs of Vitamin C Yinqiao tablets
9/26/2010
The SFDA recently issued a notice to warn against the potential adverse drug reactions (ADRs) of Vitamin C Yinqiao tablets - which combines Chinese and Western medicines and is composed of over a dozen ingredients including chlorpheniramine and paracetamol.
So far, 1,885 cases of adverse reactions of the drug, including skin disorders, allergic reactions and loss of consciousness, were reported between January 2004 and April of this year. The National Center for ADR Monitoring received 48 serious cases of side effects but there were no fatalities.
The National Center for ADR Monitoring said that such side effects were probably the result of people taking too many tablets at once, or perhaps they took other medicines with similar ingredients that were incompatible with Vitamin C Yinqiao. Some could be allergic to the tablets.
The SFDA asked doctors to remind patients about the components of the medicine and said that people who are allergic to these components should not use it. The SFDA has also ordered drug manufactures to improve package inserts and add more safety precautions.
Relate News
7/16/2024
NMPA Announces Package Insert Revision of Spleen Polypeptide Injection and Five Drugs containing Tenofovir Alafenamide
7/3/2024
NMPA Announces Package Insert Revision of Dihydroxypropyl Theophylline Injection
6/17/2024
NMPA Announces Package Insert Revision of Cyclophosphamide Adenosine, Tranexamic Acid and Aminophylline Injections
6/14/2024
CDE Issues the Technical Guidelines for the Assessment of Adverse Event Relevance in Drug Clinical Trials
more
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit